・Cronos (CRON) has demonstrated robust technical momentum, with shares up more than 20% over the past year. ・CRON maintains a 100% “Buy” rating from Barchart. ・Revenue is projected to grow 39% this ...
Although cannabis stocks have been down over the last twelve months, there has been a small rally recently. Over the last thirty days, Village Farms is up 83%, Canopy Growth up 66%, Organigram Global ...
The target increase followed Cronos' September 24, 2026 Investor Day, which presented the GrowCo facility, cannabis genetics ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Cronos reported strong Q1 performance with record-level revenue. International sales are driving growth, and the Canadian markets are showing improvement. The company is set to acquire CanAdelaar in ...
Cronos Group’s manufacturing capacity, cannabis genetics and branded product portfolio are drawing renewed attention after the company showcased its operations at an investor day, prompting an analyst ...
Cronos Group stock gained 27 percent through September 18, 2026, while second-quarter revenue rose 58 percent to USD 53 ...
Cronos Group (CRON) last issued guidance on May 9, 2023 for fiscal year 2023. The company guided revenue in the range of $100.00M - $110.00M for the period. The most recent guidance for Cronos Group ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results